胸痛患者非阻塞性冠心病的评估与内科管理:AHA科学声明
该科学声明针对胸痛患者中非阻塞性冠心病(NOCAD)的评估与管理,指出传统风险分层聚焦阻塞性CAD导致许多症状性患者被诊断为NOCAD,而2021年AHA/ACC等多学会胸痛指南拓宽了冠脉CT血管造影的应用范围,使NOCAD检出增加;人工智能与软硬件进步可识别微血管病变并在NOCAD内引入风险连续体。声明综述当前证据,强调NOCAD的药物治疗对斑块稳定和消退、降低急性冠脉综合征风险至关重要,但相关数据有限且临床存在治疗差异。
要点
- 2021年多学会胸痛指南拓宽冠脉CTA应用,使非阻塞性CAD检出增加。
- AI与软硬件进步可识别微血管病变,在NOCAD内引入风险连续体。
- NOCAD药物治疗有助于斑块稳定和消退,降低急性冠脉综合征风险。
核心结论
- 非阻塞性冠心病患者需要关注,药物治疗对斑块稳定和消退、降低急性冠脉综合征风险起重要作用。
- 尽管仅一部分胸痛患者合并非阻塞性CAD却为真性心绞痛,但 underlying 非阻塞性CAD值得重视。
- 新药治疗和无创斑块评估为斑块驱动的医疗干预提供了可能,但相关数据有限且临床存在治疗差异。
研究设计与样本
- 美国心脏协会(AHA)科学声明,综述当前非阻塞性CAD风险分层证据并讨论其意义与内科管理选择。
主要发现
- 传统风险分层聚焦阻塞性CAD,导致许多症状性个体被发现为非阻塞性CAD。
- 2021年多学会胸痛指南拓宽了心脏冠脉CT血管造影的范围,增加了非阻塞性CAD患者的识别。
- 人工智能解决方案、硬件和软件的最新进展允许识别微血管疾病,并在非阻塞性CAD内引入介于一级和二级预防之间的风险连续体。
- 仅一部分非阻塞性CAD胸痛患者为真性心绞痛。
- 非阻塞性CAD的药物治疗对斑块稳定和消退、降低急性冠脉综合征风险起重要作用。
临床怎么用
- care团队需持续更新非阻塞性CAD患者的诊断、风险分层和管理知识。
- 对非阻塞性CAD胸痛患者应考虑药物治疗以稳定和消退斑块、降低急性冠脉综合征风险。
- 可利用人工智能和无创斑块评估识别微血管疾病及非阻塞性CAD内的风险连续体。
局限性
- 非阻塞性CAD胸痛患者的数据有限。
- 临床实践中多种因素导致精准治疗机会缺失,并存在护理差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Risk stratification of patients with chest pain has traditionally focused on identifying obstructive coronary artery disease (CAD). Using this traditional approach, many symptomatic individuals are found to have nonobstructive CAD. The 2021 American Heart Association/American College of Cardiology/American Society of Echocardiography/American College of Chest Physicians/Society for Academic Emergency Medicine/Society of Cardiovascular Computed Tomography/Society for Cardiovascular Magnetic Resonance chest pain guideline widened the scope of cardiac computed coronary angiography, resulting in increased identification of patients with nonobstructive CAD. In addition, recent advances in artificial intelligence solutions, hardware, and software have allowed identification of microvascular disease and introduced new risk categories within nonobstructive CAD with a risk continuum between primary and secondary prevention. There is thus a growing need for care teams to remain current on the diagnosis, risk stratification, and management of patients with nonobstructive CAD. Whereas only a subset of patients with chest pain are found to have true angina despite nonobstructive CAD, underlying nonobstructive CAD warrants attention. Medical management of nonobstructive CAD plays an essential role in plaque stabilization and regression to decrease the risk of acute coronary syndromes. New pharmacologic therapies and noninvasive plaque evaluation raise the potential for plaque-driven medical interventions. However, data in patients with chest pain who are found to have nonobstructive CAD are limited, and, in clinical practice, multiple factors lead to missed opportunities for precision therapies, with proven disparities in care. We review the current evidence on risk stratification for nonobstructive CAD and discuss its implications and medical management options.
引用
- Slipczuk, Blankstein, Bucciarelli-Ducci, et al. State of the Art: Evaluation and Medical Management of Nonobstructive Coronary Artery Disease in Patients With Chest Pain: A Scientific Statement From the American Heart Association. Circulation. 2025. PMID: 41208705. doi:10.1161/CIR.0000000000001394
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。